Condition: Advanced Pancreatic Cancer · Metastatic Pancreatic Cancer · Sponsor: Azienda Ospedaliero-Universitaria di Modena
This is a Phase II, non-randomized, multicenter, unblinded open-label study of Olaparib in monotherapy in participants with advanced (locally advanced/metastatic) PALB2-related pancreatic cancer that have progressed after at least one treatment for advanced disease.
This description comes directly from the study's public registry record.
LAURA CORTESI, MD · +390594224334 · hbc@unimore.it
FEDERICA CAGGIA · 0594223134 · federica.caggia@unimore.it
Always discuss trial participation with your own doctor first.
| Aou Modena | Modena, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06078787